CRISTINA BEATRIZ CAZABUENA BONORINO,ANA PAULA DUARTE DE SOUZA,VINCENT GUERREIRO,DEBORAH A. RAYNES
申请号：
BR102012033804
公开号：
BR102012033804A2
申请日:
2012.12.28
申请国别(地区):
BR
年份:
2014
代理人:
摘要：
HSP70 BINDING COMPOUND, ANTI-TUMORAL PHARMACEUTICAL COMPOSITION, ITS PRODUCTION PROCESSES, TREATMENT METHOD AND USES. The present invention provides the use of the HspBP1 protein or part of it for the preparation of an anti-tumor agent, to be used in patients undergoing treatment for tumors, as well as pharmaceutical compositions containing the same or part of it, the combination being optional. with one or more chemotherapeutic agents, treatment methods using said composition, processes for obtaining and using them. The invention also provides a new experimental model in vivo for the development / evaluation of anti-tumor agents. The pharmaceutical compositions of the invention provide anti-tumor action； through the increase of circulating HsBP1, HspBP1 is bound to Hsp70 (tumor cell surface protein), resulting in its negative modulation. The pharmaceutical compositions of the present invention have high specificity to neoplastic cells, resulting in less cytotoxicity to cells of normal division, resulting, even in tumor reduction. These and other advantages of the invention are characterized as a solution to the drawbacks of currently known chemotherapeutic therapeutic regimes.COMPOSTO LIGANTE DE HSP70, COMPOSIÇÃO FARMACÊUTICA ANTI-TUMORAL, SEUS PROCESSOS DE PRODUÇÃO, MÉTODO DE TRATAMENTO E USOS. A presente invenção proporciona o uso da proteína HspBP1 ou de parte dela para a preparação de um agente anti-tumoral, a ser utilizado em pacientes em tratamento contra tumores, bem como a composições farmacêuticas contendo a mesma ou parte dela, sendo opcional a sua combinação com um ou mais agentes quimioterápicos, métodos de tratamento utilizando a referida composição, a processos para sua obtenção e uso. A invenção proporciona também um novo modelo experimental in vivo para o desenvolvimento/avaliação de agentes anti-tumorais. As composições farmacêuticas da invenção proporcionam ação anti-tumoral； através do aumento de HsBP1 circulante, ocorre a ligação de HspBP1 à Hsp
